Akums Drugs Analyst Review 2027: CDMO Engine Lifts Profit 168%, Stock Runs Past Older Targets
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Market
Akums Drugs and Pharmaceuticals Stock Snapshot (17 Nov 2026 close)
- Current Market Price (CMP): ₹716.60
- 52-Week High / Low: ₹838.80 / ₹409.30
- Market Capitalisation: ₹11,280 crore
- P/E Ratio vs Industry P/E: 30.9 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹1,342 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹114.57 crore
Quick Answer: The Akums Drugs analyst review 2027 is led by a sharp jump in earnings. Q2 FY27 revenue rose about 31.9% to ₹1,342 crore, EBITDA more than doubled to ₹195 crore and profit rose about 168% to ₹114.57 crore. Earlier brokerage targets, ICICI Securities at ₹680 and Citi at ₹610 from February 2026, now sit below the 17 November close of ₹716.60. The stock trades near 31 times trailing earnings, below its industry P/E of about 40, so the Akums Drugs share price target 2027 depends on whether CDMO margins above 15% can last.
The Akums Drugs analyst review 2027 covers India’s largest contract development and manufacturing company for domestic formulations. Anyone searching for an Akums Drugs share price target 2027 will find that the business has moved faster than the published targets, which were set when the stock traded near ₹490.
Akums Drugs and Pharmaceuticals closed at ₹716.60 on 17 November 2026, about 15% below its 52-week high of ₹838.80 and about 75% above its low of ₹409.30. This Akums Drugs analyst review 2027 covers the brokerage calls, the September quarter and the Akums Drugs stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Akums Drugs Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| ICICI Securities | Buy | ₹680 (raised from ₹600) | February 2026 |
| Citi | Buy | ₹610 | February 2026 |
ICICI Securities raised its target to ₹680 from ₹600 in February 2026 after Q3 FY26, when CDMO revenue grew about 16%. It forecast an 11.2% revenue CAGR, 20.4% EBITDA CAGR and 16.7% profit CAGR over FY25 to FY28, with EBITDA margin rising by about 300 basis points to 14.2% by FY28. Citi also had a Buy rating with a ₹610 target at that time.
The Q2 FY27 margin of 14.5% is already above ICICI Securities’ FY28 estimate, two years early. That is why the stock has moved past both targets. At ₹716.60, the price is about 5% above the ₹680 target and about 17% above Citi’s ₹610.
The key point in this Akums Drugs analyst review 2027 is that the targets are dated. Each brokerage is likely to revisit its estimates after the September quarter, and new figures would reset the Akums Drugs share price target 2027 range.
Q2 FY27 Results in the Akums Drugs Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from Operations | ₹1,342 crore | ₹1,018 crore | +31.9% |
| EBITDA | ₹195 crore | ₹94 crore | +106% |
| EBITDA Margin | 14.5% | 9.3% | +520 bps |
| Net Profit | ₹114.57 crore | ₹42.70 crore | +168% |
| CDMO Revenue | ₹1,115 crore | ₹804 crore | +38.6% |
| CDMO EBITDA Margin | 15.1% | 10.5% | +460 bps |
Revenue rose about 31.9% from a year earlier and about 15.1% from the June quarter. EBITDA more than doubled to about ₹195 crore, and margin widened to 14.5% from 9.3%. Profit after tax rose about 168% to ₹114.57 crore.
Profit has now risen for four straight quarters, from ₹42.70 crore to ₹67.67 crore, ₹81.34 crore, ₹100.98 crore and ₹114.57 crore. CDMO made up about 83% of revenue. The API business was weak, with revenue down about 35% to ₹29 crore. For the Akums Drugs analyst review 2027, the quarter confirms that the main engine is running well ahead of plan.
How Akums Drugs Makes Money
Akums manufactures medicines for other pharma companies, which then sell them under their own brands.
- CDMO: contract development and manufacturing of tablets, capsules, liquids, injectables and other formulations for Indian and global pharma brands.
- Branded formulations: its own branded generics sold in India.
- API: active pharmaceutical ingredients, a smaller and currently weaker segment.
- International: exports and supply to overseas partners.
FY26 revenue was about ₹4,488 crore and profit about ₹256 crore. Operating cash flow jumped to about ₹1,181 crore in FY26 from ₹465 crore in FY25. Strong cash conversion and near-zero debt are important points in the Akums Drugs analyst review 2027.
Growth Triggers in the Akums Drugs Analyst Review 2027
- CDMO momentum: CDMO revenue grew 38.6% and H1 CDMO EBITDA rose to ₹332 crore from ₹204 crore.
- Margin guidance: management has guided to full-year EBITDA margin of 14% to 15%, and Q2 hit 14.5%.
- Outsourcing trend: Indian pharma brands keep shifting manufacturing to specialist contract makers.
- Clean balance sheet: debt to equity of about 0.03 gives room for capex.
- Foreign interest: foreign investors raised their stake to 4.50% from 2.28%, an early sign of support in the Akums Drugs analyst review 2027.
Key Risks in the Akums Drugs Analyst Review 2027
- Margin sustainability: a jump of more than 500 basis points in a year may not repeat.
- API weakness: API revenue fell about 35% in Q2 FY27.
- Dated targets: named targets of ₹610 and ₹680 are below the market price.
- Client concentration: CDMO depends on large pharma brand owners renewing contracts.
- Pricing rules: drug price controls in India can squeeze customer margins and, in turn, contract pricing.
- Low return on equity: about 10.4%, though rising with profit.
Compare Akums Drugs With Pharma CDMO Stocks on the Univest Screener
Akums Drugs Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (17 Nov 2026 close) | ₹716.60 |
| 52-Week High / Low | ₹838.80 / ₹409.30 |
| Market Capitalisation | ₹11,280 crore |
| P/E (TTM) vs Industry | 30.9 vs 40.1 |
| Price to Book | 3.22 |
| Book Value per Share | ₹222.61 |
| Return on Equity | 10.39% |
| Debt to Equity | 0.03 |
| EPS (TTM) | ₹23.16 |
| FY26 Revenue / Net Profit | ₹4,487.7 crore / ₹256.4 crore |
A P/E near 31 is below the pharma industry level of about 40, and price to book value is about 3.2. Trailing earnings still include weaker quarters, so the ratio would look lower if the latest run rate holds. In the Akums Drugs analyst review 2027, valuation is not the main hurdle.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 75.26% | 75.26% | No change |
| Foreign Investors (FII) | 2.28% | 4.50% | +2.22 pts |
| Domestic Institutions (DII) | 9.28% | 11.08% | +1.80 pts |
| Public | 13.19% | 9.15% | -4.04 pts |
The promoter group, led by the Akums Master Trust at 40.79% and Sandeep Jain at 17.24%, holds a steady 75.26%. Both foreign and domestic institutions added stakes while retail holders sold, a shift that often follows a profit turnaround. That institutional buying is a supportive sign in the Akums Drugs analyst review 2027.
What to Watch After the Akums Drugs Analyst Review 2027
- CDMO margin: whether it stays above 15% in Q3 and Q4 FY27.
- API recovery: signs that the API segment stabilises after a 35% fall.
- New contracts: wins with large domestic and global pharma brands.
- Capex plans: capacity additions funded from strong operating cash flow.
- Brokerage updates: revised targets after Q2 FY27 would refresh the Akums Drugs share price target 2027.
Final Word on the Akums Drugs Analyst Review 2027
The Akums Drugs analyst review 2027 shows a CDMO business that has hit its margin targets early, with Q2 FY27 profit up about 168% and EBITDA margin at 14.5%. Named brokerage targets from February 2026 now sit below the price, which reflects how fast results have improved.
The Akums Drugs stock outlook 2027 depends on holding CDMO margins above 15% and fixing the weak API segment. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Akums Drugs analyst review 2027 show?
It shows a strong earnings jump led by contract manufacturing. Q2 FY27 revenue rose about 31.9% to ₹1,342 crore and profit rose about 168% to ₹114.57 crore. EBITDA margin widened to 14.5% from 9.3%.
What is the Akums Drugs share price target 2027 from brokerages?
ICICI Securities had a Buy rating with a ₹680 target and Citi a Buy with ₹610, both from February 2026. The stock closed at ₹716.60 on 17 November 2026, above both. Updated targets after Q2 FY27 would give a fresher reference.
How did the CDMO business perform in Q2 FY27?
CDMO revenue rose 38.6% to ₹1,115 crore, about 83% of total revenue. CDMO EBITDA margin rose to 15.1% from 10.5%. H1 CDMO EBITDA increased to ₹332 crore from ₹204 crore.
How does Akums Drugs make money?
It manufactures medicines for other pharma companies under contract, which is its CDMO business. It also sells its own branded formulations and makes APIs. FY26 revenue was about ₹4,488 crore.
Is Akums Drugs expensive, based on the Akums Drugs analyst review 2027?
The P/E of about 30.9 is below the industry figure of about 40.1. Price to book is about 3.2 and debt to equity is near 0.03. Trailing earnings still include weaker quarters from a year ago.
What risks does the Akums Drugs analyst review 2027 highlight?
The main risks are whether margins stay at current levels and the weak API segment, where revenue fell about 35%. Published brokerage targets are below the market price. Drug price controls can also affect contract pricing.
What should investors track after the Akums Drugs analyst review 2027?
Track CDMO margin in Q3 and Q4 FY27 against the 14% to 15% guidance. Watch for API recovery and new manufacturing contracts. Revised brokerage targets after Q2 FY27 will also matter.